In the pipeline from Derek Lowe – Page 4
-
OpinionIt's complicated
In a complex world, binary answers are often requested but rarely sufficient
-
Opinion
Management by numbers
Reducing intellectual processes to metrics runs the risk of people working to the numbers not the goal
-
OpinionWould you buy synthetic wine?
Can we replicate the chemical profiles of famously expensive drinks? And would people drink them?
-
OpinionWe’re going to need a bigger flask
Scaling up reactions is easy to get wrong in a variety of ways
-
OpinionWhat are the rate-limiting steps in drug discovery?
Getting more drugs to market is not just a chemistry problem
-
OpinionHow science shapes our psychology
We learn to embrace the unexpected, follow evidence over opinion and accept that most experiments fail
-
OpinionWhat would a 1980s student make of modern research?
Nano- and macromolecular science might make for a shocking read in the launderette
-
OpinionThe projects drug companies wish they’d never started
Failures are common in drug research, but some are bigger than others
-
-
OpinionFeeding the confusion
When it comes to working out what foods do to our bodies, mostly we just don’t know
-
-
Opinion'If I'd discovered metformin, I'd have tossed it aside...'
Trusting our intuition too strongly highlights how little we know about chemical activity
-
OpinionThe three muses of scientific discovery
Inspiration, experimentation and happy accidents are all pathways to a breakthrough
-
OpinionWhy combination pills aren’t always the answer
The challenges of medicines containing multiple drugs aren’t going away
-
OpinionWill robots make you redundant?
Smart machines could soon outpace even the best organic chemist
-
-
OpinionWhy modern chemists need to think big
The lessons we can learn from the larger reaction scales of the past
-
OpinionFor the sake of argument
It’s important to recognise which disputes can actually be resolved by science
-
BusinessTargeting rare diseases
Is working on genetic mutations that affect only a few in every thousand people risky?
-
OpinionRise of the biologics
Antibodies, RNA and gene therapy don’t necessarily compete with small molecule drugs – and they all rely on chemistry